New study tests cheaper breast cancer screening for High-Risk women
NCT ID NCT06629896
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study compares contrast-enhanced mammography (CEM) to the standard MRI plus digital mammography for screening women at high risk of breast cancer. About 2200 women aged 35-60 with a 5-year risk of 5% or higher will be randomly assigned to one of the two screening methods over two rounds. The goal is to see if CEM, which is faster and less expensive, can detect breast cancer just as well as MRI.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Contrast-enhanced mammography (CEM) and magnetic resonance imaging (MRI) with digital mammography
- What this could lead to
- If CEM works as well as MRI, it could offer a faster, cheaper, and more accessible screening option for women at high risk of breast cancer.
- What could go wrong
- This is a Phase 2 trial with 2200 participants, so results are preliminary. CEM may not detect cancers as accurately as MRI, and the study only follows women for 2.5 years.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER SCREENING AND DIAGNOSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Istituto in tecnologie avanzate e modelli assistenziali in oncologia - AUSL-IRCCS Reggio Emilia
RECRUITINGReggio Emilia, Italy/Reggio Emilia, 42122, Italy
More trials for these conditions
Other studies related to the condition(s) this trial covers.